Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

NCT04507841 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

67

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: Niraparib

Sponsor

Tongji Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]